Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo -reduced susceptibility to piperaquine. Neither the exonuclease E415G mutation nor the copy number variation of the plasmepsin II gene ( Pfpm2 ), associated with piperaquine resistance in Cambodia, was detected in Senegalese parasites.
All Keywords
【저자키워드】 in vitro, malaria, resistance, Piperaquine, Plasmodium falciparum, antimalarial drug, Molecular marker, Plasmepsin II,
【저자키워드】 in vitro, malaria, resistance, Piperaquine, Plasmodium falciparum, antimalarial drug, Molecular marker, Plasmepsin II,